Whalesbook
Achanak Q3 mein itni tez tezi kaise?
Asal mein, Pfizer India ne apne revenue ko iss quarter mein 19.9% tak badhaya, jo ₹645 crore pahunch gaya. Iske saath hi, company ne costs ko bhi kaafi ache se manage kiya, jiski wajah se EBITDA 55.8% badh kar ₹228.3 crore ho gaya. Yeh sab effort milakar operating margins 27.2% se sudhar kar 35.4% tak pahunch gaye. Ye numbers dikhate hain ki company apni operational efficiency mein kaafi sudhaar kar rahi hai aur growth ko bottom line mein convert kar paa rahi hai.
Share Price Reaction Dekho!
Jaise hi yeh results aane ki khabar mili, earnings announcement se pehle hi Pfizer Limited ka share 3.91% badh kar ₹4,770 par band hua tha. Investors ko company ki performance kaafi pasand aayi.
Competition Aur Valuation Ka Scene
Ab agar company ke valuation ki baat karein, toh iska market cap lagbhag ₹21,776 crore hai aur P/E ratio 30.8x ke aas-paas hai. Agar doosre pharma giants se compare karein, toh Sun Pharma ka P/E 33.7x hai aur Dr. Reddy's ka 19.12x. Indian pharma sector overall 7-9% growth expect kar raha hai FY2026 mein, par competition bhi kaafi tagda hai, especially generics mein.
Kya Hai Risk Factor?
Results acche hone ke bawajood, kuch cheezein dhyan mein rakhni chahiye. Pharma market mein bohot competition hai, aur raw material costs ya currency mein fluctuations aati rehti hain. Pfizer India apne established products par depend karta hai, jahan patent expiry aur biosimilars ka risk ho sakta hai. Saath hi, pichle paanch saal mein company ki sales growth sirf 1.18% rahi hai, jo thodi kam lagti hai.
Aage Kya Ho Sakta Hai?
Future mein, company apni operational efficiency aur margins ko maintain kar paati hai ya nahi, ye dekhna important hoga. Analysts ka 'Strong Buy' rating hai aur price target mein upside ka potential dikh raha hai. Lekin parent company Pfizer Inc. ke liye 2026 mein revenue flat rehne ka forecast hai, jo shayad Indian subsidiary par bhi thoda asar daal sakta hai.